FDA's plan to boost cheaper copycat drugs could stall at patent office
The FDA's push for lower-cost medicines looks good on paper, but the patent office under President Trump may be going in the opposite direction.
The FDA's push for lower-cost medicines looks good on paper, but the patent office under President Trump may be going in the opposite direction.
Read the full article at:
CBS News →